La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Orexo Gestion

Gestion contrôle des critères 2/4

Le PDG Orexo's est Nikolaj Sorensen, nommé en Feb2013, a un mandat de 11.5 ans. La rémunération annuelle totale est SEK 6.12M, composée du salaire de 59.5% et des bonus 40.5%, y compris les actions et options de la société. détient directement 0.52% des actions de la société, d'une valeur de SEK 2.81M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 4.3 ans.

Informations clés

Nikolaj Sorensen

Directeur général

SEK 6.1m

Rémunération totale

Pourcentage du salaire du PDG	59.5%
Durée du mandat du directeur général	11.6yrs
Propriété du PDG	0.5%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	4.4yrs

Mises à jour récentes de la gestion

Recent updates

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Aug 02

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 20

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Sep 09

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

May 26

Is Orexo (STO:ORX) Using Too Much Debt?

Apr 16

Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?

May 04

Analyse de la rémunération des PDG

Comment la rémunération de Nikolaj Sorensen a-t-elle évolué par rapport aux bénéfices de Orexo?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-SEK 97m
Mar 31 2024	n/a	n/a	-SEK 73m
Dec 31 2023	SEK 6m	SEK 4m	-SEK 128m
Sep 30 2023	n/a	n/a	-SEK 201m
Jun 30 2023	n/a	n/a	-SEK 195m
Mar 31 2023	n/a	n/a	-SEK 218m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 178m
Sep 30 2022	n/a	n/a	-SEK 152m
Jun 30 2022	n/a	n/a	-SEK 177m
Mar 31 2022	n/a	n/a	-SEK 216m
Dec 31 2021	SEK 10m	SEK 4m	-SEK 223m
Sep 30 2021	n/a	n/a	-SEK 207m
Jun 30 2021	n/a	n/a	-SEK 240m
Mar 31 2021	n/a	n/a	-SEK 198m
Dec 31 2020	SEK 9m	SEK 3m	-SEK 84m
Sep 30 2020	n/a	n/a	SEK 4m
Jun 30 2020	n/a	n/a	SEK 201m
Mar 31 2020	n/a	n/a	SEK 288m
Dec 31 2019	SEK 6m	SEK 3m	SEK 219m
Sep 30 2019	n/a	n/a	SEK 232m
Jun 30 2019	n/a	n/a	SEK 182m
Mar 31 2019	n/a	n/a	SEK 178m
Dec 31 2018	SEK 5m	SEK 3m	SEK 138m
Sep 30 2018	n/a	n/a	SEK 113m
Jun 30 2018	n/a	n/a	SEK 79m
Mar 31 2018	n/a	n/a	SEK 32m
Dec 31 2017	SEK 6m	SEK 4m	SEK 23m

Rémunération vs marché: La rémunération totale de Nikolaj ($USD 596.28K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 278.75K ).

Rémunération et revenus: La rémunération de Nikolaj a augmenté alors que l'entreprise n'est pas rentable.

PDG

Nikolaj Sorensen (52 yo)

11.6yrs

Titularisation

SEK 6,118,000

Compensation

Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He is Director at Gesynta Pharma AB. He has been the Chief Executive Officer of Orexo AB since Febr...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Nikolaj Sorensen	President & CEO	11.6yrs	SEK 6.12m	0.52% SEK 2.5m
Fredrik Jarrsten	Executive VP & CFO	2.1yrs	pas de données	0.076% SEK 364.0k
Cecilia Coupland	Senior VP & Head of Operations	5.7yrs	pas de données	0.042% SEK 200.0k
Lena Wange	Investor Relations & Communications Director	no data	pas de données	pas de données
Robert Ronn	Senior VP and Head of R&D	5.7yrs	pas de données	0.059% SEK 281.9k
Edward Kim	Chief Medical Officer	1.9yrs	pas de données	pas de données
Robert Deluca	President of Orexo US Inc	11.7yrs	pas de données	0.027% SEK 130.6k
Jesper Lind	Advisor	no data	pas de données	pas de données

5.7yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ORX est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
George Wilkinson	Independent Director	5.4yrs	SEK 400.00k	0.056% SEK 266.9k
James Noble	Independent Chairman of the Board	4.4yrs	SEK 1.50m	0.19% SEK 896.8k
Staffan Lindstrand	Independent Director	22.7yrs	SEK 450.00k	0.099% SEK 474.6k
Christine Rankin	Independent Director	2.4yrs	SEK 550.00k	0.023% SEK 110.2k
Robin Evers	Independent Director	less than a year	SEK 50.00k	pas de données

4.4yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ORX sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).

Orexo Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

Independent Chairman of the Board recently bought kr361k worth of stock

Executive VP & CFO recently bought kr81k worth of stock

Recent updates

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Consensus EPS estimates fall by 45%

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 10% to kr21.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Consensus EPS estimates upgraded to kr1.95 loss

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr28.00

Orexo AB (publ) Announces Board Appointments

Is Orexo (STO:ORX) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

Director recently bought kr505k worth of stock

Consensus forecasts updated